Sai Life Sciences' Q2 FY 2025-26 Quarterly Results
- 06 Jan 2026
Result Summary
- Sai Life Sciences Ltd reported a 9.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 36.3%.
- Its expenses for the quarter were up by 3.6% QoQ and 25.9% YoY.
- The net profit increased 38.7% QoQ and increased 102.0% YoY.
- The earnings per share (EPS) of Sai Life Sciences Ltd stood at 3.93 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 552.80 | 506.32 | 405.52 | 9.2% | 36.3% |
Total Expenses | 440.74 | 425.57 | 350.19 | 3.6% | 25.9% |
Profit Before Tax | 112.05 | 80.75 | 55.32 | 38.8% | 102.5% |
Tax | 28.21 | 20.29 | 13.81 | 39.0% | 104.3% |
Profit After Tax | 83.84 | 60.46 | 41.51 | 38.7% | 102.0% |
Earnings Per Share | 3.93 | 2.83 | 2.21 | 38.9% | 77.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sai Life Sciences Ltd is a notable entity in the pharmaceutical sector, primarily engaged in providing services related to drug discovery, development, and manufacturing. The company operates in the contract research and manufacturing services (CRAMS) industry, which supports pharmaceutical and biotechnology companies in their drug development processes. Sai Life Sciences has been recognized for its capabilities in delivering integrated services, ranging from early discovery to commercial supply. As of the most recent updates available, there are no significant public announcements regarding new partnerships or major developments. However, the industry as a whole continues to evolve with advancements in biopharmaceuticals and precision medicine, which may impact companies like Sai Life Sciences.
Revenue
In Q2FY26, Sai Life Sciences Ltd reported a total income of ₹552.80 crores. This represents a quarter-over-quarter (QoQ) increase of 9.2% from the ₹506.32 crores recorded in Q1FY26. On a year-over-year (YoY) basis, the total income saw a significant rise of 36.3% compared to ₹405.52 crores in Q2FY25. This upward trajectory in revenue indicates a sustained growth in the company's income over both the quarterly and annual periods. The financial data reflects a robust expansion in revenue, suggesting effective revenue generation strategies and possibly an increase in demand for the company's services.
Profitability
The profitability for Sai Life Sciences Ltd in Q2FY26 can be observed from key financial metrics. The company achieved a profit before tax (PBT) of ₹112.05 crores, marking a substantial QoQ growth of 38.8% from ₹80.75 crores in Q1FY26. Compared to the same quarter in the previous year, PBT increased by 102.5% from ₹55.32 crores. After accounting for taxes, the profit after tax (PAT) stood at ₹83.84 crores, a QoQ rise of 38.7% and a YoY hike of 102.0% from ₹41.51 crores in Q2FY25. The earnings per share (EPS) for the quarter was ₹3.93, reflecting an increase of 38.9% QoQ and 77.8% YoY. These figures demonstrate a strong performance in terms of profitability, with significant growth both quarterly and annually.
Operating Metrics
Analyzing the operating metrics for Sai Life Sciences Ltd, total expenses for Q2FY26 were reported at ₹440.74 crores, which signifies a 3.6% increase QoQ from ₹425.57 crores in Q1FY26 and a 25.9% rise YoY from ₹350.19 crores in Q2FY25. The tax expense for the quarter was ₹28.21 crores, showing a QoQ growth of 39.0% and a YoY increase of 104.3%. These figures indicate an increase in operating costs and tax liabilities, which have grown alongside the company's overall revenue and profitability. Despite the rise in expenses, the company managed to maintain a healthy growth in net profits, as evidenced by the substantial YoY and QoQ gains in profitability metrics.